Study Evaluating IMA-026 in Healthy Japanese Males
Phase 1
Completed
- Conditions
- Healthy
- Registration Number
- NCT00528099
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ascending, single subcutaneous or intravenous doses of IMA-026 in healthy Japanese male subjects
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 50
Inclusion Criteria
- Men ages 20 to 40 years, inclusive, at screening
- Body mass index (BMI) in the range of 17.6 to 26.4 kg/m2 and body weight > 45 kg
- Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vitals signs, and 12 lead ECG.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method To assess the safety and PK profile of IMA-026 administered as single ascending subcutaneous or intravenous doses. 6 months
- Secondary Outcome Measures
Name Time Method